Abstract
Biotechnology Law ReportVol. 35, No. 3 Original ArticlesPrior Art Status of Drug Standard Evidence in China's Pharmaceutical Patent Invalidation ProcessYu Ji and Feixiang GuoYu JiSearch for more papers by this author and Feixiang GuoSearch for more papers by this authorPublished Online:20 Jun 2016https://doi.org/10.1089/blr.2016.29014.jyAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byGeneric Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China Li Jiang and Hong Yang5 August 2022 | Biotechnology Law Report, Vol. 41, No. 4 Volume 35Issue 3Jun 2016 InformationCopyright 2016, Mary Ann Liebert, Inc.To cite this article:Yu Ji and Feixiang Guo.Prior Art Status of Drug Standard Evidence in China's Pharmaceutical Patent Invalidation Process.Biotechnology Law Report.Jun 2016.93-97.http://doi.org/10.1089/blr.2016.29014.jyPublished in Volume: 35 Issue 3: June 20, 2016PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
